The FDA has approved [ Keytruda (pembrolizumab) ] plus pemetrexed and platinum chemotherapy in the frontline treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. Data from the phase 2/3 KEYNOTE-483 study (NCT02784171) showed that [ Keytruda (pembrolizumab) ] plus chemotherapy (n = 222) significantly … [Read more...]
Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment
Abstract: The combination of cisplatin and pemetrexed remains the gold standard chemotherapy for malignant pleural mesothelioma (MPM), although resistance and poor response pose a significant challenge. Cytidine deaminase (CDA) is a key enzyme in the nucleotide salvage pathway and is involved in the adaptive stress response to chemotherapy. The … [Read more...]
Challenging the Norm: Occurrence of Synchronous Pleural and Peritoneal Mesothelioma in a Female Patient
Abstract: Here, we present a unique case involving a female patient in her 40s with synchronous malignant pleural and peritoneal mesothelioma, despite lacking a history of asbestos exposure. The patient's initial symptoms included dyspnoea, chest pain, cough, fever, appetite loss, and weight loss over a month. Clinical evaluation led to the … [Read more...]
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study
Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint inhibition (ICI) has taken center stage in the currently ongoing revolution that is changing standard-of-care treatment for several malignancies, including MPM. As multiple arguments and accumulating lines of evidence are … [Read more...]
Malignant Pleural Mesothelioma: Analysis of 70 Cases in the Last Decade
Malignant Pleural Mesothelioma (MPM) is an aggressive tumor linked to asbestos exposure, with a latency period of about 40 years before symptoms appear. Despite affecting a minority of exposed individuals, its risk escalates with prolonged exposure. Originating from mesothelial cells, [ Malignant Pleural Mesothelioma (MPM) ] affected 30,870 … [Read more...]
FDA Fast Tracks UV1, Ipilimumab, and Nivolumab in Malignant Mesothelioma
The FDA has granted a fast track designation to the combination of UV1 with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma. This regulatory decision is supported by findings from the phase 2 NIPU trial which is evaluating UV1 in patients with unresectable malignant pleural mesothelioma. … [Read more...]
Exhaled Breath May Predict Treatment Outcomes in Patients With Mesothelioma
The identification of volatile organic compounds (VOCs) in exhaled breath is a promising opportunity for noninvasive detection and prediction of treatment outcomes in patients with mesothelioma, according to data from a pilot study presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, held … [Read more...]
Feladilimab by GSK for Malignant Pleural Mesothelioma: Likelihood of Approval
[Feladilimab] is under development [by the pharmaceutical company GSK] for the treatment of [malignant pleural mesothelioma], advanced solid tumors including non-small cell lung cancer, squamous non-small cell lung cancer, bladder cancer, cervical cancer, esophageal, urothelial cancer, clear renal cell carcinoma, head and neck cancer squamous cell … [Read more...]
Malignant Pleural Mesothelioma (MPM) Presenting as Hydropneumothorax
An 86-year-old man presented with bilateral lower limb edema and was found to have hydropneumothorax on chest radiography. CT revealed a substantial pleural effusion and plaques. The patient had a history of working in a stone workshop, but the extent of asbestos exposure remained unknown. Thoracic drainage and subsequent thoracoscopic surgery … [Read more...]
Merck reports positive data from malignant pleural mesothelioma trial
Merck and the Canadian Cancer Trials Group (CCTG) have reported positive data from the Phase II/III CCTG IND.227/KEYNOTE-483 trial of Keytruda, along with chemotherapy, as first-line treatment for advanced malignant pleural mesothelioma patients. The open-label, randomised Phase II/III trial has been designed for assessing the combination of … [Read more...]